BSLN Stock Overview
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF34.75 |
| 52 Week High | CHF55.40 |
| 52 Week Low | CHF33.95 |
| Beta | 0.73 |
| 1 Month Change | -0.29% |
| 3 Month Change | -27.30% |
| 1 Year Change | -29.30% |
| 3 Year Change | -33.17% |
| 5 Year Change | -21.80% |
| Change since IPO | -65.59% |
Recent News & Updates
Recent updates
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Shareholder Returns
| BSLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -0.6% | 9.7% | 1.4% |
| 1Y | -29.3% | -26.0% | -1.1% |
Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned -26% over the past year.
Return vs Market: BSLN underperformed the Swiss Market which returned -1.1% over the past year.
Price Volatility
| BSLN volatility | |
|---|---|
| BSLN Average Weekly Movement | 3.0% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: BSLN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BSLN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 143 | David Veitch | https://www.basilea.com |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
Basilea Pharmaceutica AG Fundamentals Summary
| BSLN fundamental statistics | |
|---|---|
| Market Cap | CHF416.31m |
| Earnings (TTM) | CHF56.20m |
| Revenue (TTM) | CHF175.02m |
7.4x
P/E Ratio2.4x
P/S RatioIs BSLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSLN income statement (TTM) | |
|---|---|
| Revenue | CHF175.02m |
| Cost of Revenue | CHF77.80m |
| Gross Profit | CHF97.22m |
| Other Expenses | CHF41.02m |
| Earnings | CHF56.20m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 13, 2024
| Earnings per share (EPS) | 4.69 |
| Gross Margin | 55.55% |
| Net Profit Margin | 32.11% |
| Debt/Equity Ratio | 1,008.0% |
How did BSLN perform over the long term?
See historical performance and comparison